EyEnovIA, Inc. Files 8-K for Material Definitive Agreement

TL;DR

EYEN just signed a big deal, details to come.

AI Summary

On September 26, 2024, EyEnovIA, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company, incorporated in Delaware with its principal executive offices in New York, NY, is involved in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates a significant business development for EyEnovIA, Inc., potentially impacting its operations, partnerships, or financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks depending on the undisclosed terms.

Key Players & Entities

• EYENOVIA, INC. (company) — Registrant
• September 26, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• New York, NY (location) — Principal Executive Offices
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.0001 — on which registered) Common stock, $0.0001 par value EYEN The Nasdaq Stock Mar
• $0.46 — each Share and accompanying Warrant is $0.46 . The combined offering price for each
• $0 — ded Warrant and accompanying Warrant is $0.4599, which is equal to the purchase pr
• $0.50 — March 31, 2030 at an exercise price of $0.50 per share. The exercise price and numbe
• $4.0 million — fering are expected to be approximately $4.0 million. The Company intends to use the net pro

Filing Documents

• tm2425134d1_8k.htm (8-K) — 38KB
• tm2425134d1_ex4-1.htm (EX-4.1) — 99KB
• tm2425134d1_ex4-2.htm (EX-4.2) — 97KB
• tm2425134d1_ex5-1.htm (EX-5.1) — 15KB
• tm2425134d1_ex10-1.htm (EX-10.1) — 172KB
• tm2425134d1_ex99-1.htm (EX-99.1) — 11KB
• tm2425134d1_ex5-1img001.jpg (GRAPHIC) — 23KB
• tm2425134d1_ex5-1img002.jpg (GRAPHIC) — 14KB
• tm2425134d1_ex5-1img003.jpg (GRAPHIC) — 4KB
• 0001104659-24-103959.txt ( ) — 769KB
• eyen-20240926.xsd (EX-101.SCH) — 3KB
• eyen-20240926_lab.xml (EX-101.LAB) — 33KB
• eyen-20240926_pre.xml (EX-101.PRE) — 22KB
• tm2425134d1_8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this Current Report on Form 8-K are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements relating to the Company's future activities or other future events or conditions, including statements regarding the completion of the Offering, the intended use of net proceeds from the Offering, and potential regulatory approvals and accessible markets for the Company's product candidates. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which the Company files with the SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, the Company does not undertake any obligation to update any forward-looking statements.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 27, 2024, the Company issued a press release announcing the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Warrant. 4.2 Form of Pre-Funded Warrant. 5.1 Opinion of Covington & Burling LLP. 10.1 Form of Securities Purchase Agreement, dated September 26, 2024. 23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1). 99.1 Press Release, dated September 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: September 30, 2024 /s/ Andrew Jones Andrew Jones Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR